INTRODUCTION
Only four vancomycin-resistant Staphylococcus aureus (VRSA) isolates have been reported so far from the USA (Chang et al., 2003; Tenover et al., 2004; CDC, 2004; Weigel et al., 2007; Perichon & Courvalin, 2006) . There has been no report of a van gene-mediated VRSA from Asia as yet, except for vancomycin-intermediate S. aureus (VISA) in Japan (CDC, 1997) and Korea (Kim et al., 2000) . Recently, Tiwari & Sen (2006) have reported a VRSA which is van gene-negative. Staphylococcus can cause a variety of suppurative diseases in man, including skin, heart-valve, blood and bone infections (Morse, 1980) . More than 90 % of Staphylococcus strains are resistant to penicillin (Chambers, 2001) , followed by increasing resistance to meticillin, aminoglycosides, macrolides and lincosamide (Dickgiesser & Kreiswirth, 1986; Levin et al., 2005; Munckhof et al., 2002; Schmitz et al., 2000) . In view of this antibiotic resistance, vancomycin has been the drug of last resort. Vancomycin, a glycopeptide antibiotic, acts against Gram-positive bacteria only, by inhibiting the incorporation of NAM-NAG-polypeptide into the growing peptidoglycan (PG) chain. It inhibits this process by reacting with D-Ala-D-Ala, which consequently blocks the release of terminal D-Ala and intrachain bond formation. Vancomycin-resistant Enterococcus faecium harbours the vanA operon, which contains five genes, vanS, -R, -H, -A and -X (Arthur et al., 1993) . vanS and vanR are the regulator genes (Wright et al., 1993 (Bugg et al., 1991a) , which could be used by VanA ligase in conjunction with ATP and D-Ala to make a D-Ala-D-lactate depsipeptide (Bugg et al., 1991b) , which is incorporated into the PG layer. Vancomycin binds to Nacyl-D-Ala-D-lactate with an affinity 1000-fold lower than that of N-acyl-D-Ala-D-Ala (Bugg et al., 1991b) . VanX is a dipeptidase required for the hydrolysis of D-Ala-D-Ala (Reynolds et al., 1994) . Conjugative transfer of high-level vancomycin resistance from Enterococcus faecalis to S. aureus (Noble et al., 1992) , and transfer of glycopeptide-and macrolide-resistance genes by transconjugation among enterococci and from Ent. faecalis to S. aureus (Młynarczyk et al., 2002) , have been reported. Vancomycin-resistance gene acquisition by S. aureus from Ent. faecium in the clinical environment has also been reported by Weigel et al. (2007) .
In this study, we have shown the emergence of vancomycin resistance in Kolkata, India, and its conjugative transfer from one clinical strain to another.
METHODS
Bacterial strains. Fifty-seven non-repeat clinical isolates of S. aureus were collected from various Kolkata hospitals, namely the Calcutta Medical College and Hospital, the School of Tropical Medicine, the Institute of Child Health, the R. G. Kar Medical College and Hospital, the Nilratan Sirkar Medical College and Hospital, and the Seth Sukhlal Karnani Medical College and Hospital, from January 2002 to December 2005. Earlier, 126 strains of S. aureus were collected from the Calcutta Medical College and Hospital during the period November 1985 to September 1988. All these strains were collected to study the antibiotic-resistance profile of S. aureus. All cultures were grown on nutrient agar (NA) medium and purified by a single colony isolation technique on NA containing 10 % sodium chloride. Escherichia coli V517 was obtained from National Institute of Cholera and Enteric Disease (NICED).
Confirmation of species identification. Identification of the clinical isolates of S. aureus was performed by traditional biochemical tests, including catalase, coagulase and mannitol fermentation tests, and Gram staining (Bannerman, 2003; Turk & Porter, 1978) . PCR amplification of the nuc gene (Brakstad et al., 1992) was performed only for VRSA STM2. PCR amplification of 16S rDNA was also performed for VRSA STM2, induced STM2, MC48 and transconjugant T48.
Antibiotic susceptibility testing. The antibiotic-resistance profile was determined by the disc agar diffusion (DAD) technique (Acar, 1980; Bauer et al., 1966) , using 18 antibiotic discs. Among these antibiotics, some discs were prepared in the Microbiology Laboratory, Department of Physiology, and a few were obtained commercially from Himedia. The antimicrobials, the manufacturers and the amounts (mg) of antimicrobial per disc were as follows: amoxicillin (Rexcel, 30 mg) (NCCLS, 2000) .
Isolation of plasmid DNAs. For molecular studies, plasmid DNAs from the clinical isolate S. aureus STM2 and the reference strain E. coli V517, which contains six plasmids of molecular weights 53.4, 5.5, 5.1, 3, 2.7 and 2.1 kb (Macrina et al., 1978) , were isolated using the QIAGEN Midi plasmid purification kit, following the manufacturer's instruction of prewarming the elution buffer (Buffer EB) to 50 uC for elution of large plasmids.
Preparation of genomic DNA. The crude lysates of clinical isolates of S. aureus STM2 (VRSA), MC48 (vancomycin-sensitive S. aureus; VSSA) and T48 (transconjugant) were prepared by sucrose-mediated detergent lysis (Saha et al., 1989) . Cell lysates were treated with proteinase K (10 mg ml 21 , preactivated at 37 uC for 30 min) at room temperature for 30 min. NaCl (1.44 ml, 5 M) was added to this mixture and incubated at 65 uC for 20 min. An equal volume of chloroform : isoamyl alcohol (24 : 1, v/v) mixture was added, and the aqueous layer was extracted with an equal volume of phenol : chloroform : isoamyl alcohol (25 : 24 : 1, v/v). The aqueous phase was again extracted twice with chloroform : isoamyl alcohol (24 : 1, v/v), and DNA was precipitated by the addition of chilled ethanol. The DNA pellet was washed with cold 70 % ethanol and reconstituted in Tris/ EDTA buffer. The genomic DNA was treated with RNase and stored at 220 uC.
PCR. PCR amplification was performed with an ABI 9700 thermal cycler in a volume of 50 ml. For amplification of the nuc gene and mecA, the following components were used: 1.5 mM MgCl 2, 200 mM each of dATP, dTTP, dGTP and dCTP, 2 mM of each primer, 0.1 mg template DNA, and 1.25 U Taq polymerase (Invitrogen).
(i) PCR amplification of the nuc gene. A partial nuc gene was amplified using nuc gene primers (Table 1) , which were selected on the basis of the published nucleotide sequence of the 966 bp nuc gene derived from the S. aureus Foggi strain (Brakstad et al., 1992) . The cycling parameters consisted of 30 cycles of denaturation at 94 uC for 30 s, primer annealing at 50 uC for 1 min, and extension at 72 uC for 1 min 30 s.
(ii) PCR amplification of mecA. For amplification of mecA, oligonucleotide primers (Table 1) were used (Dias et al., 2004) . The reaction conditions were 30 cycles of denaturation at 94 uC for 40 s, primer annealing at 52 uC for 45 s, and extension at 72 uC for 30 s.
(iii) PCR amplification of vanHAX, vanH, vanA and vanX. The PCR amplification mixture contained the following components: 16 Phusion GC buffer containing 1.5 mM MgCl 2 , 200 mm each dNTP, 2 mm each primer, 0.1 mg template DNA, 3 % (v/v) DMSO and 1 U Phusion DNA polymerase (Finnzymes). The amplification conditions were initial denaturation at 98 uC for 2 min, followed by 35 cycles of denaturation at 98 uC for 10 s; annealing at 50 uC for 1 min; polymerization at 72 uC for 1 min 30 s for van HAX, 60 s for both vanH and vanA, and 30 s for vanX; and final extension at 72 uC for 5 min for all. The primer sequences specific for vanHAX, vanH, vanA and vanX (Donabedian et al., 2000) are given in Table 1 .
Transfer of vancomycin resistance by mating procedure. Broth mating (Clewell et al., 1985; Philippon et al., 1983) was performed as follows. Single colonies of donor and recipient cells were inoculated separately in Luria-Bertani (LB) broth and grown overnight at 37 uC with shaking. These overnight cultures were diluted 1 : 100 in fresh medium, and each was grown to early exponential phase (OD 600 0.6). Mating mixture was prepared by adding 0.1 ml of donor cells to 0.9 ml of recipient cells, and was swirled gently for a few minutes and then incubated at 37 uC for 6 h (without shaking), followed by plating (0.2 ml per plate) on Luria agar (LA) medium containing 16 mg vancomycin ml 21 and 2.5 mg ciprofloxacin ml 21 . Colonies were counted after 48 and 72 h of incubation. Donor and recipient cells were also plated separately to check their disability to grow on the vancomycin plus ciprofloxacin plate, because the donor was ciprofloxacin-sensitive and the recipient was susceptible to vancomycin.
Nucleotide sequencing. Amplified PCR products (vanHAX and vanH) were purified with the Wizard SV Gel and PCR Clean Up System (Promega). The gel-eluted PCR products were sequenced with an ABI Prism automated DNA sequencer (Applied Biosystems) with the single primer (forward primer for vanH, reverse primer for vanHAX). The sequencing reaction was carried out using 5 pmol primer and the BigDye Terminator v3.1 Cycle Sequencing kit (Applied Biosystems), following the instructions of the manufacturer. The sequencing amplification conditions were as follows: 96 uC for 10 s, 50 uC for 10 s and 60 uC for 4 min for 25 cycles. After the sequencing PCR, the products (10 ml reaction volume) were treated with 2 ml 125 mM EDTA (pH 8.0), and then precipitated using 2 ml 3 M sodium acetate (pH 4.6) and 50 ml absolute ethanol for 20 min at room temperature (in the dark). The DNA was recovered by centrifugation, washed with 70 % alcohol, dried and resuspended in 15 ml Hi-Di formamide (Applied Biosystems). Sequencing was performed in an ABI PRISM 3130 Genetic Analyzer. Raw sequences were edited and assembled using the Auto Assembler program. The resulting sequences were used for identification with the help of the NCBI BLASTN program.
RESULTS AND DISCUSSION

Source and identification of strain
The clinical isolate S. aureus STM2, which was found to be VRSA, was obtained from the School of Tropical Medicine (STM), Kolkata. The strain was isolated from the pus of an outpatient. No other case history could be found. Isolates MC48 and MC50 were obtained from pus samples from separate patients at the Calcutta Medical College and Hospitals.
The clinical isolates were identified using standard biochemical tests. All were catalase-and coagulase-positive. The isolates took 72 h to grow in mannitol-salt (10 % NaCl) agar medium.
The thermostable nuclease-encoding nuc gene is highly specific for S. aureus. PCR amplification of the nuc gene of VRSA STM2 using the gene-specific primers (Table 1 ) and the chromosomal DNA preparation yielded a 270 bp amplicon, as expected (data not shown). This result confirmed VRSA STM2 as an S. aureus strain.
PCR amplification of 16S rDNA of the clinical isolates VRSA STM2 and S. aureus MC48 using primers specific for staphylococcal 16S rRNA (Table 1 ) produced an identical Table 1 . Sequences of primers and sizes of PCR-amplified products of different genes of S. aureus All primers were obtained from Clonitec. The references of the primers are as follows: nuc (Brakstad et al., 1992) ; 16S rRNA of S. aureus (Woo et al., 2003) ; mecA (Dias et al., 2004) ; vanHAX (Donabedian et al., 2000) ; vanH, vanA and vanX (this study).
Specific gene for amplification Primer
Primer sequence (5 §-3 §) Strain no. 1.5 kb amplicon of 16S rDNA in both the strains (Woo et al., 2003) . The VRSA STM2 with a vancomycin MIC of 1024 mg ml 21 was named STM2-I (induced STM2). An identical 1.5 kb amplicon was also obtained from STM2-I and the transconjugant T48. These PCR results again confirmed the identity of MC48, STM2, STM2-I and T48 as S. aureus.
Antimicrobial susceptibility tests
On initial testing, the growth of VRSA STM2 on the NA screen plate containing 32 mg vancomycin ml 21 suggested possible vancomycin resistance. Further confirmation of vancomycin resistance was obtained from the DAD test, since no zone of inhibition surrounding the vancomycin disc was noted.
The VRSA STM2 isolate was resistant to many antibiotics, i.e. amoxicillin, ampicillin, cefepime, cefotaxime, cefuroxime, cephalexin, chloramphenicol, clindamycin, erythromycin, meticillin, rifampicin, roxithromycin, streptomycin, trimethoprim-sulfamethoxazole and vancomycin. However, it was susceptible to gentamicin and ciprofloxacin, as determined by the DAD test (Table 2 ).
The MIC of vancomycin for the VRSA STM2 isolate was found to be 64 mg ml
21
, which confirmed it as VRSA by NCCLS criteria. However, the MIC value increased to 1024 mg ml 21 after subculturing of this strain in the presence of vancomycin. This observation indicates the inducible nature of the vancomycin resistance of VRSA STM2. It has been suggested by Arthur and co-workers that the vanA gene cluster (vanR, vanS, vanH, vanA and vanX) carried by Tn1546 is responsible for inducible resistance to high levels of glycopeptides in Ent. faecium BM4147 and Ent. faecalis (Arthur et al., 1993; Reynolds et al., 1994) . This suggestion validates our observation of an increasing MIC value for vancomycin (64 to 1024 mg ml 21 ), and the inducible nature of resistance to high levels of vancomycin in VRSA STM2 might be due to the presence of the vanA gene cluster. The PCR and sequencing experiments further confirmed the presence of the vanA gene cluster (discussed below). Glycopeptide antibiotics, vancomycin and teicoplanin, are used to treat severe infections due to multidrug-resistant Gram-positive bacteria (including MRSA). However, treatment with vancomycin to alleviate this type of bacterial infection that has inducible resistance to high levels of the antibiotic itself would be a therapeutic failure, and might even be fatal for the patient.
Plasmid analysis
The plasmid profile of VRSA STM2 revealed five plasmids: one large plasmid of~53.4 kb, and four small plasmids of 6,~5.5,~5.1 and~1.5 kb, when compared with the molecular size of plasmid markers of the reference strain E. coli V517 (Fig. 1) . 
Emergence of vancomycin-resistant S. aureus in India
Transfer of vancomycin resistance by transconjugation
Twenty-one transconjugant colonies were found on LA plates containing appropriate selective antibiotics (16 mg vancomycin ml 21 and 2.5 mg ciprofloxacin ml
21
) taking VRSA STM2 (ciprofloxacin-sensitive) as a donor, and vancomycin-sensitive ciprofloxacin-resistant S. aureus MC48 as a recipient (Table 2) . However, no transconjugant colony was found on the above LA medium with VRSA STM2 as the donor and vancomycin-sensitive ciprofloxacin-resistant S. aureus MC50 (Table 2) as the recipient. No growth of recipient S. aureus strains MC48 and MC50, and the donor strain VRSA STM2, was observed on the above LA medium when inoculated separately. A selected transconjugant (named S. aureus T48) was observed to grow even after three successive overnight passages on NA plates containing 32 mg vancomycin ml
. This indicated successful and stable transfer of vancomycin resistance from the clinical isolate VRSA STM2 donor to another clinical isolate S. aureus MC48 as recipient. While the MIC of vancomycin for the transconjugant T48 was 32 mg ml 21 , that of the recipient S. aureus MC48 strain was 2 mg ml 21 .
PCR-based detection of vancomycin-resistance genes (vanHAX, vanH, vanA and vanX) and mecA in VRSA STM2
Initially, genomic DNA was used as template for PCR amplification of vanHAX, vanH and vanX, using primers specific for vanHAX (2.6 kb), vanH (969 bp) and vanX (609 bp) (Donabedian et al., 2000) , as shown in Table 1 . PCR products of 2.6 kb for vanHAX, 1 kb for vanH and 600 bp for vanX were obtained, which suggests the presence of the vanHAX gene cassette in VRSA STM2.
Later, the plasmid preparation obtained using the QIAGEN kit was used as template for PCR amplification of vanHAX (2.61 kb), vanH (969 bp), vanA (1032 bp) and vanX (609 bp) with the appropriate primers. Amplicons of 2.6 kb for vanHAX,~1 kb for vanH,~1.1 kb for vanA and 500 bp for vanX were obtained (Fig. 2) . The results confirmed the possession of van genes by the plasmid(s) of VRSA STM2. Most probably, the genomic DNA preparation had plasmid DNA contamination, and that was the reason for obtaining PCR products of vanHAX using genomic DNA as template.
Finally, the specific plasmid(s) that harboured the van genes was identified. Each plasmid was eluted from the gel, purified by using the gel-extraction kit (Promega), and used as template for PCR amplification of vanHAX, vanH, vanA and vanX separately using the specific primers for those genes (Table 1) . Only in the case of the 53.4 kb plasmid were the same amplicons obtained as by PCR using the whole plasmid preparation (containing all the plasmids of different sizes) as template (Fig. 2) . This result clearly established that the 53.4 kb plasmid harbours the vancomycin-resistance gene cluster vanHAX in VRSA STM2. A 2.3 kb amplicon was also obtained from STM2-I and transconjugant T48 using primers specific for the vanHAX gene cassette. A 1 kb amplicon was obtained from VRSA STM2, STM2-I and transconjugant T48 using primers specific for the vanH gene (969 bp) (Fig. 3, Table 1 ). However, no 2.3 or 1 kb amplicon was observed in the case of VSSA MC48 (Fig. 3) . A 600 bp amplicon was also obtained from VRSA STM2, STM2-I and transconjugant T48 using primers specific for the vanX gene (609 bp) (data not shown). However, no such amplicon was observed in the case of VSSA MC48 using these primers. These results suggested the presence of a vanA gene cassette in VRSA STM2 and STM2-I that mediates high-level vancomycin resistance through alterations of the PG layer of the cell wall and cell-wall metabolism.
PCR amplification of vanHAX, vanH and vanX of transconjugant T48 (Fig. 3) clearly indicated the transfer of the same vancomycin-resistance genes vanHAX from the donor VRSA STM2 to the recipient VSSA MC48.
The meticillin resistance of VRSA STM2 was verified by PCR amplification of the mecA gene; an amplicon of 0.3 kb was obtained (data not shown).
Nucleotide sequencing
Nucleotide sequencing of 652 bases (GenBank accession no. EU019995) with the forward primer of the 1 kb PCR product of vanH showed 47 % homology with the nucleotide sequence of the VanH dehydrogenase of the Tn1546-like element, and 44 % homology with Tn1549 (Garnier et al., 2000) . VanH dehydrogenase reduces pyruvate to lactate, one of the building blocks of the PG layer of the cell wall of S. aureus. VanH dehydrogenase, which is functionally like lactate dehydrogenase, is a common metabolic enzyme required for glycolysis and the tricarboxylic acid (TCA) cycle (carbohydrate metabolism), and is ubiquitous in nature. Accordingly, in the VRSA STM2 strain, a mechanism exists that facilitates the expression of VanH dehydrogenase and VanA ligase to form D-Ala-D-lactate. Nucleotide sequencing of 272 bases with the reverse primer of the 2.3 kb PCR product of vanHAX produced a sequence (GenBank accession no. EU016096) that had 45 % homology with, and a region of 21 bases identical to, the Tn1546-like element that contains the vanHAX gene cluster. This sequence also showed 56 % homology with Tn1549, which is responsible for vanB-type vancomycin resistance in Ent. faecalis (Garnier et al., 2000) . However, the PCR product vanA (Fig. 2) Noble et al. (1992) . Intrageneric transfer of such high-level vancomycin and other antibiotic resistance from S. aureus to S. aureus has also been reported (Severin et al., 2004; Pawa et al., 2000) . However, in this study, we have demonstrated intrageneric transfer of vancomycin resistance from a clinical strain of S. aureus to another clinical isolate of S. aureus, which has alarming implications for the global dissemination of such high-level glycopeptide resistance in clinical settings with no known effective antibiotic therapy for some Gram-positive bacterial infections.
In summary, the major new findings of the present study are:
(1) This is believed to be the first report of VRSA containing mecA and the vanA gene complex from Kolkata, India, as well as South Asia.
(2) The vancomycin resistance of the clinical isolate VRSA STM2 is inducible in vitro.
(3) PCR amplification and nucleotide sequencing experiments suggest the presence of a vanHAX-type gene cluster, analogous to that of the Tn1546-like element, in VRSA STM2 and transconjugant T48.
(4) The vancomycin resistance obtained in VRSA STM2 is plasmid-mediated and transferable to a sensitive clinical isolate (as found for VSSA MC48).
The emergence of inducible VRSA in Kolkata, India (as well as in South Asia), and its intrageneric transfer is alarming. This may soon become a global problem, unless antimicrobial agents are used more prudently. Scientists, clinicians and other healthcare professionals should identify and report VRSA promptly for appropriate care and treatment of patients, and start to implement infection-control precautions to prevent the spread of VRSA. 
